Condition
Ulcerative Colitis
Clear, practical articles to help you understand Ulcerative Colitis symptoms, medications, flares, nutrition, and everyday disease management. Browse our articles below.
Omvoh vs Stelara for Ulcerative Colitis: Patient Guide
Omvoh and Stelara both target IL-23 pathway inflammation in moderate-to-severe ulcerative colitis, but with different mechanism specificity and clinical profiles. Stelara is an IL-12/23 p40 biologic approved for UC in October 2019 based on UNIFI. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on LUCENT-1 and LUCENT-2. Patients choosing between these two non-anti-TNF IL-23 pathway drugs often weigh mechanism specificity, urgency outcomes, and long-term dosing. This guide walks through the omvoh vs stelara ulcerative colitis decision.
Omvoh vs Remicade for Ulcerative Colitis: Patient Guide
Omvoh and Remicade represent two very different approaches to treating moderate-to-severe ulcerative colitis. Remicade has been the anti-TNF standard for UC since the mid-2000s. Omvoh is a newer IL-23 p19-selective biologic that gained UC approval in October 2023 based on the LUCENT-1 and LUCENT-2 trials. Patients commonly compare these drugs when starting a first biologic or considering alternatives after Remicade has lost effect. This guide walks through the omvoh vs remicade ulcerative colitis decision.
Omvoh vs Humira for Ulcerative Colitis: Which Is Right?
Omvoh and Humira take different mechanistic approaches to moderate-to-severe ulcerative colitis. Humira is the established anti-TNF with more than a decade of UC experience. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on the LUCENT-1 and LUCENT-2 trials, making it the first drug in its class approved for UC. Patients choosing between these drugs weigh mechanism, safety, and long-term administration convenience. This guide walks through the omvoh vs humira ulcerative colitis decision.
Omvoh vs Entyvio for Ulcerative Colitis: A Comparison
Omvoh and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on the LUCENT-1 and LUCENT-2 trials. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or seek alternatives to anti-TNF therapy. This guide walks through the omvoh vs entyvio ulcerative colitis comparison.
Humira vs Remicade for Ulcerative Colitis: Patient Guide
Humira and Remicade are the two most widely prescribed anti-tumor necrosis factor (anti-TNF) biologics for ulcerative colitis. Both have treated moderate-to-severe UC for more than fifteen years, both are now available as lower-cost biosimilars, and both can help patients reach steroid-free remission. The choice between them usually comes down to how you want to receive your medication, how your insurance handles biosimilars, and which practical trade-offs fit your life. This guide walks through what UC patients typically weigh when deciding between humira vs remicade ulcerative colitis therapy.
Entyvio vs Stelara for Ulcerative Colitis: Which to Choose?
Entyvio and Stelara are two of the most common biologics used for ulcerative colitis after a patient has failed an anti-TNF, and they are increasingly considered first-line options as well. Both avoid the systemic TNF blockade that raises infection risk in anti-TNF therapy, but they do so through very different mechanisms. Entyvio is gut-selective. Stelara blocks an upstream cytokine pathway that affects inflammation throughout the body. For UC patients weighing a second-line biologic or looking for a safer first-line option, the decision often hinges on onset of action, efficacy in anti-TNF experienced patients, and dosing convenience. This guide walks through the evidence UC patients need to make an informed entyvio vs stelara ulcerative colitis decision.
Entyvio vs Remicade for Ulcerative Colitis: Comparing Biologics
Entyvio and Remicade are the two most commonly used intravenous biologics for ulcerative colitis. Remicade is a broad anti-tumor necrosis factor agent with decades of real-world data. Entyvio is a gut-selective biologic that acts almost exclusively on the intestines. For UC patients who want infusion-based therapy but are weighing targeted vs systemic action, this is a common comparison. This guide walks through the evidence on entyvio vs remicade ulcerative colitis across mechanism, efficacy, safety, and practical considerations.
Entyvio vs Humira for Ulcerative Colitis: Head-to-Head
Entyvio and Humira are two of the most commonly prescribed biologics for ulcerative colitis, and they represent very different approaches to quieting inflammation. Humira is a systemic anti-TNF that affects immune signaling throughout the body. Entyvio is gut-selective and acts almost exclusively in the intestines. Uniquely for biologic comparisons in UC, there is direct head-to-head randomized trial data. The VARSITY trial compared these two drugs directly, and the results have meaningfully shaped how gastroenterologists think about first-line biologic choice in UC. This guide walks through the evidence patients need to make an informed entyvio vs humira ulcerative colitis decision.
When Your UC Biologic Stops Working: Next Steps
Lost response to your UC biologic? Here's how to navigate what comes next.
Understanding Your UC Lab Results: CRP, Calprotectin, and More
What your UC lab results actually mean and how to use them.
Ulcerative Proctitis: When UC Is Limited to the Rectum
Your guide to proctitis treatment, progression risk, and why it's not 'mild.'
Ulcerative Colitis and Body Image: What Nobody Talks About
Why UC changes how you see yourself, and what actually helps.